429 related articles for article (PubMed ID: 35386715)
1. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
2. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract][Full Text] [Related]
4. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract][Full Text] [Related]
5. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
[TBL] [Abstract][Full Text] [Related]
6. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
7. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
Khan M; Zhao Z; Arooj S; Fu Y; Liao G
Front Immunol; 2020; 11():587460. PubMed ID: 33329567
[TBL] [Abstract][Full Text] [Related]
8. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
Front Immunol; 2022; 13():830606. PubMed ID: 35935985
[TBL] [Abstract][Full Text] [Related]
9. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
Bailly C; Thuru X; Quesnel B
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204509
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
13. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
14. Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Zhou K; Guo S; Li F; Sun Q; Liang G
Front Cell Dev Biol; 2020; 8():569219. PubMed ID: 33178688
[TBL] [Abstract][Full Text] [Related]
15. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
[TBL] [Abstract][Full Text] [Related]
17. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
18. Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.
Zhu L; Xu Y; Kang S; Lin B; Zhang C; You Z; Lin H; Yang C; Song Y
Small Methods; 2022 Sep; 6(9):e2200549. PubMed ID: 35810463
[TBL] [Abstract][Full Text] [Related]
19. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
20. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
